Regeneron (REGN) Reports Positive 2-Yr Results from Phase 3 PANORAMA Trial Evaluating EYLEA (aflibercept) Injection 2mg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron Pharma (REGN) PT Raised to $465 at SVB Leerink
February 7, 2020 8:59 AM ESTSVB Leerink analyst Marc Goodman raised the price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $454.00) while maintaining a Outperform rating.... More
Regeneron Pharma (REGN) PT Raised to $400 at SunTrust
February 7, 2020 7:11 AM ESTSunTrust analyst Robyn Karnauskas raised the price target on Regeneron Pharma (NASDAQ: REGN) to $400.00 (from $360.00) while maintaining a Hold rating.... More
Regeneron Pharma (REGN) PT Raised to $420 at Credit Suisse
February 7, 2020 6:26 AM ESTCredit Suisse analyst Evan Seigerman raised the price target on Regeneron Pharma (NASDAQ: REGN) to $420.00 (from $400.00) while maintaining a Outperform rating.... More
Regeneron Pharma (REGN) PT Raised to $400 at SunTrust
February 7, 2020 6:24 AM ESTSunTrust analyst Robyn Karnauskas raised the price target on Regeneron Pharma (NASDAQ: REGN) to $400.00 (from $360.00) while maintaining a Hold rating.
The analyst commented, "We updated our model to reflect 4Q19 results and added Dupixent revenues from pediatric AD, resulting in our PT going... More
Regeneron Pharma (REGN) PT Lowered to $410 at Morgan Stanley
February 7, 2020 5:31 AM ESTMorgan Stanley analyst Matthew Harrison lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $410.00 (from $411.00) while maintaining a Equalweight rating.... More
Regeneron Pharma (REGN) PT Raised to $405 at Bernstein
February 6, 2020 4:17 PM ESTBernstein analyst Aaron Gal raised the price target on Regeneron Pharma (NASDAQ: REGN) to $405.00 (from $375.00) while maintaining a Market Perform rating.
... MoreRegeneron Pharma (REGN) PT Raised to $355 at Jefferies
February 6, 2020 1:53 PM ESTJefferies analyst Biren Amin raised the price target on Regeneron Pharma (NASDAQ: REGN) to $355.00 (from $341.00) while maintaining a Hold rating following results.
... MoreRegeneron (REGN) Tops Q4 EPS by 58c
February 6, 2020 6:32 AM ESTRegeneron (NASDAQ: REGN) reported Q4 EPS of $7.50, $0.58 better than the analyst estimate of $6.92. Revenue for the quarter came in at $2.17 billion versus the consensus estimate of $2.11 billion.
The Company and Sanofi announced intent to restructure antibody collaboration for Kevzara and Praluent2020... More
Drugmaker Sanofi expects further profit growth from narrowed focus
February 6, 2020 1:51 AM ESTBy Matthias Blamont
PARIS (Reuters) - French drugmaker Sanofi on Thursday forecast further profit growth for 2020 even as it drops some research in areas such as diabetes in a shake-up to narrow its focus on blockbuster treatments including eczema medicine Dupixent.
Sanofi, long viewed as a laggard in the pharmaceutical sector, has changed its chief executive, its chief financial officer and head of research over the past two years and is hoping to shine again thanks to the pipeline shake-up and cost cuts.
The company... More
